Clinical trial NCT00261118 - References

Ulcerative Colitis — Rituximab in Active Ulcerative Colitis

Citation(s)

•   Arzoo K, Sadeghi S, Liebman HA
  Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002 Oct;61(10):922-4.
•   Cohen RD, Stein R, Hanauer SB
  Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun;94(6):1587-92.
•   Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C
  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.
•   De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G
  Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002 Aug;46(8):2029-33.
•   Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C
  A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989 Mar;96(3):804-10.
•   Hibi T, Ohara M, Kobayashi K, Brown WR, Toda K, Takaishi H, Hosoda Y, Hayashi A, Iwao Y, Watanabe M, et al
  Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut. 1994 Feb;35(2):224-30.
•   Inoue N, Watanabe M, Sato T, Okazawa A, Yamazaki M, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T
  Restricted V(H) gene usage in lamina propria B cells producing anticolon antibody from patients with ulcerative colitis. Gastroenterology. 2001 Jul;121(1):15-23.
•   Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA
  An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673-7.
•   Leandro MJ, Edwards JC, Cambridge G
  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002 Oct;61(10):883-8.
•   Looney RJ
  Treating human autoimmune disease by depleting B cells. Ann Rheum Dis. 2002 Oct;61(10):863-6. Review.
•   Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R
  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457-66.
•   McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK
  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.
•   Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F
  Immunoregulation in the gut: success and failures in human disease. Gut. 2002 May;50 Suppl 3:III60-4. Review.
•   Papadakis KA, Rosenbloom B, Targan SR
  Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology. 2003 Feb;124(2):583.
•   Patel DD
  B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 2002 Aug;46(8):1984-5. Review.
•   Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D
  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998 Jun;42(6):788-91.
•   Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P
  Rituximab for idiopathic membranous nephropathy. Lancet. 2002 Sep 21;360(9337):923-4. Erratum in: Lancet 2002 Dec 21-28;360(9350):2090.
•   Schroeder KW, Tremaine WJ, Ilstrup DM
  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9.
•   Specks U, Fervenza FC, McDonald TJ, Hogan MC
  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001 Dec;44(12):2836-40.
•   Stack WA, Long RG, Hawkey CJ
  Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther. 1998 Oct;12(10):973-8.
•   Stasi R, Pagano A, Stipa E, Amadori S
  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952-7.
•   Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC
  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002 Oct;110(7):955-63.

Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis

Details for clinical trial NCT00261118